[A new case of complete isolated diphallus].

C. Lassen,L. Huguenin,P. Vergnes,M. Kohout,A. Coulin,Y. Hermouet

1987-10-01

Abstract:

What problem does this paper attempt to address?

Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast Cancer chemotherapy: The ONCORE randomized controlled trial

Estíbaliz Díaz-Balboa,Carlos Pena-Gil,Beatriz Rodríguez-Romero,Antonio I. Cuesta-Vargas,Oscar Lado-Baleato,Amparo Martínez-Monzonís,Milagros Pedreira-Pérez,Patricia Palacios-Ozores,Rafael López-López,José R. González-Juanatey,Violeta González-Salvado

DOI: https://doi.org/10.1016/j.pcad.2024.02.002

IF: 11.278

2024-02-22

Progress in Cardiovascular Diseases

Abstract:Background Breast cancer (BC) treatment with anthracyclines and/or anti-human epidermal growth factor receptor-2 (HER2) antibodies is associated with an increased risk of cardiovascular disease complications, including cancer therapy-related cardiac dysfunction (CTRCD). While Cardio-Oncology Rehabilitation (CORe) programs including exercise have emerged to minimize these risks, its role in preventing CTRCD is unclear. Objectives We investigated the effectiveness of an exercise-based CORe program in preventing CTRCD [left ventricular ejection fraction (LVEF) drop ≥10% to a value 15% in global longitudinal strain (GLS)]. Secondary outcomes examined changes in cardiac biomarkers, physical performance including peak oxygen consumption, psychometric and lifestyle outcomes. Safety, adherence, and patient satisfaction were also assessed. Methods This is a randomized controlled trial including 122 early-stage BC women receiving anthracyclines and/or anti-HER2 antibodies, randomized to CORe ( n = 60) or usual care with exercise recommendation ( n = 62). Comprehensive assessments were performed at baseline and after cardiotoxic treatment completion. The average duration of the intervention was 5.8 months. Results No cases of CTRCD were identified during the study. LVEF decreased in both groups, but was significantly attenuated in the CORe group [−1.5% (−2.9, −0.1); p = 0.006], with no changes detected in GLS or cardiac biomarkers The CORe intervention led to significant body mass index (BMI) reduction ( p = 0.037), especially in obese patients [3.1 kg/m 2 (1.3, 4.8)]. Physical performance and quality-of-life remained stable, while physical activity level increased in both groups. No adverse events were detected. Conclusions This study suggests that CORe programs are safe and may help attenuate LVEF decline in BC women receiving cardiotoxic therapy and reduce BMI in obese patients.

cardiac & cardiovascular systems
Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)

Rebecca H Maier,Chris Plummer,Adetayo S Kasim,Nasima Akhter,Emmanuel Ogundimu,Jamie Maddox,Janine Graham,Michael Stewart,Andrew Wardley,Sophie Haney,Sharareh Vahabi,Helen Oxenham,Alison Humphreys,Nicola Cresti,Mark Verrill,Richard Graham,Lisa Chang,Helen C Hancock,David Austin

DOI: https://doi.org/10.1136/bmjopen-2022-066252

IF: 3.006

2022-12-31

BMJ Open

Abstract:Introduction Anthracyclines are included in chemotherapy regimens to treat several different types of cancer and are extremely effective. However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines can cause irreversible damage to cardiac cells and ultimately impaired cardiac function and heart failure, which may only be evident years after exposure. The PROACT trial will establish the effectiveness of the ACE inhibitor enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin's lymphoma (NHL) receiving anthracycline-based chemotherapy. Methods and analysis PROACT is a prospective, randomised, open-label, blinded end-point, superiority trial which will recruit adult patients being treated for breast cancer and NHL at NHS hospitals throughout England. The trial aims to recruit 106 participants, who will be randomised to standard care (high-dose anthracycline-based chemotherapy) plus enalapril (intervention) or standard care alone (control). Patients randomised to the intervention arm will receive enalapril (starting at 2.5 mg two times per day and titrating up to a maximum dose of 10 mg two times per day), commencing treatment at least 2 days prior to starting chemotherapy and finishing 3 weeks after their last anthracycline dose. The primary outcome is the presence or absence of cardiac troponin T release at any time during anthracycline treatment, and 1 month after the last dose of anthracycline. Secondary outcomes will focus on cardiac function measured using echocardiogram assessment, adherence to enalapril and side effects. Ethics and dissemination A favourable opinion was given following research ethics committee review by West Midlands—Edgbaston REC, Ref: 17/WM/0248. Trial findings will be disseminated through engagement with patients, the oncology and cardiology communities, NHS management and commissioning groups and through peer-reviewed publication. Trial registration number NCT03265574.

medicine, general & internal
Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study

Stephen J Foulkes,Erin J Howden,Mark J Haykowsky,Yoland Antill,Agus Salim,Sophie S Nightingale,Sherene Loi,Piet Claus,Kristel Janssens,Amy M Mitchell,Leah Wright,Ben T Costello,Anniina Lindqvist,Lauren Burnham,Imogen Wallace,Robin M Daly,Steve F Fraser,André La Gerche

DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.062814

IF: 37.8

2023-02-14

Circulation

Abstract:Background: Breast cancer survivors treated with anthracycline-based chemotherapy (AC) have increased risk of functional limitation and cardiac dysfunction. We conducted a 12-month randomized controlled trial in 104 patients with early-stage breast cancer scheduled for AC to determine whether 12 months of exercise training (ExT) could attenuate functional disability (primary end point), improve cardiorespiratory fitness (VO2peak), and prevent cardiac dysfunction. Methods: Women 40 to 75 years of age with stage I to III breast cancer scheduled for AC were randomized to 3 to 4 days per week aerobic and resistance ExT for 12 months (n=52) or usual care (UC; n=52). Functional measures were performed at baseline, at 4 weeks after AC (4 months), and at 12 months, comprising: (1) cardiopulmonary exercise testing to quantify VO2peak and functional disability (VO2peak ≤18.0 mL·kg-1·min-1); (2) cardiac reserve (response from rest to peak exercise), quantified with exercise cardiac magnetic resonance measures to determine changes in left and right ventricular ejection fraction, cardiac output, and stroke volume; (3) standard-of-care echocardiography-derived resting left ventricular ejection fraction and global longitudinal strain; and (4) biochemistry (troponin and BNP [B-type natriuretic peptide]). Results: Among 104 participants randomized, greater study attrition was observed among UC participants (P=0.031), with 93 women assessed at 4 months (ExT, n=49; UC, n=44) and 87 women assessed at 12 months (ExT, n=49; UC, n=38). ExT attenuated functional disability at 4 months (odds ratio, 0.32 [95% CI, 0.11-0.94]; P=0.03) but not at 12 months (odds ratio, 0.27 [95% CI, 0.06-1.12]; P=0.07). In a per-protocol analysis, functional disability was prevented entirely at 12 months among participants adherent to ExT (ExT, 0% versus UC, 20%; P=0.005). Compared with UC at 12 months, ExT was associated with a net 3.5-mL·kg-1·min-1 improvement in VO2peak that coincided with greater cardiac output, stroke volume, and left and right ventricular ejection fraction reserve (P<0.001 for all). There was no effect of ExT on resting measures of left ventricular function. Postchemotherapy troponin increased less in ExT than in UC (8-fold versus 16-fold increase; P=0.002). There were no changes in BNP in either group. Conclusions: In women with early-stage breast cancer undergoing AC, 12 months of ExT did not attenuate functional disability, but provided large, clinically meaningful benefits on VO2peak and cardiac reserve. Registration: URL: https://www.anzctr.org.au/; Unique identifier: ACTRN12617001408370.
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study

Giulia Borgonovo,Elen Vettus,Alessandra Greco,Laura Anna Leo,Francesco Fulvio Faletra,Catherine Klersy,Moreno Curti,Mariacarla Valli

DOI: https://doi.org/10.2196/31887

2022-04-21

Abstract:Background: The incidence of breast cancer is rising worldwide. Recent advances in systemic and local treatments have significantly improved survival rates of patients having early breast cancer. In the last decade, great attention has been paid to the prevention and early detection of cardiotoxicity induced by breast cancer treatments. Systemic therapy-related cardiac toxicities have been extensively studied. Radiotherapy, an essential component of breast cancer treatment, can also increase the risk of heart diseases. Consequently, it is important to balance the expected benefits of cancer treatment with cardiovascular risk and to identify strategies to prevent cardiotoxicity and improve long-term outcomes and quality of life for these patients. Objective: This CardioTox Breast study aims to investigate the use of cardiac imaging, based on cardiac magnetic resonance and echocardiography, and to identify associated circulating biomarkers to assess early tissue changes in chemo-induced and radiation-induced cardiotoxicity in the time window of 12 months after the end of radiotherapy in patients with breast cancer. Methods: The CardioTox Breast trial is a multicenter observational prospective longitudinal study. We aim to enroll 150 women with stage I-III unilateral breast cancer, treated with breast conserving surgery, who planned to receive radiotherapy with or without systemic therapy. Baseline and follow-up data include cardiac measurements based on cardiac magnetic resonance imaging, echocardiography, and circulating biomarkers of cardiac toxicity. Results: This study details the protocol of the CardioTox Breast trial. Recruitment started in September 2020. The results of this study will not be published until data are mature for the final analysis of the primary study end point. Conclusions: The CardioTox Breast study is designed to investigate the effects of systemic and radiation therapy on myocardial function and structure, thus providing additional evidence on whether cardiac magnetic resonance is the optimal screening imaging for cardiotoxicity. Trial registration: ClinicalTrials.gov NCT04790266; https://clinicaltrials.gov/ct2/show/NCT04790266. International registered report identifier (irrid): DERR1-10.2196/31887.
TITAN Trial: A Randomized Controlled Trial of a Cardiac Rehabilitation Care Model in Breast Cancer

Amy A Kirkham,John R Mackey,Richard B Thompson,Mark J Haykowsky,Gavin Y Oudit,Margaret McNeely,Richard Coulden,Michael K Stickland,Vickie E Baracos,Jason R B Dyck,Robert Haennel,Edith Pituskin,D Ian Paterson

DOI: https://doi.org/10.1016/j.jacadv.2023.100424

2023-07-27

Abstract:Background: Cardiac rehabilitation (CR) modeled care is recommended for patients with breast cancer to mitigate risk of cardiotoxicity. However, the cardiovascular impact of CR-modeled interventions has not been studied. Objectives: The purpose of this study was to evaluate if a multidisciplinary model of CR reduces cardiotoxicity and improves cardiovascular risk in patients undergoing breast cancer treatment. Methods: We randomly assigned patients with stage I to III breast cancer scheduled to receive anthracycline and/or trastuzumab-based chemotherapy to the CR intervention (n = 37) or usual care (n = 37). The intervention included guideline-directed management of cardiovascular risk factors, dietary counselling, and supervised exercise for 52 weeks. Cardiac magnetic resonance imaging, cardiopulmonary exercise testing, dual-energy x-ray absorptiometry, and serum biomarkers were acquired at baseline and 52 weeks. Results: There was no difference in the primary outcome, left ventricular ejection fraction (LVEF), between groups at 52 weeks (61% ± 6%). Other markers of cardiotoxicity, including high-sensitivity troponin I and brain natriuretic peptide, were similar between groups. However, total cholesterol (5.2 ± 0.8 mmol/L to 4.7 ± 0.8 mmol/L, P = 0.002) and low-density lipoprotein (3.0 ± 0.7 mmol/L to 2.4 ± 0.7 mmol/L, P < 0.001) decreased in the intervention group at 52 weeks and were unchanged in usual care. In all patients, adverse cardiac and metabolic changes occurred over 52 weeks including reductions in LVEF, left ventricular mass, high-density lipoprotein, lean body mass, insulin-like growth factor-1, as well as increased triglycerides, whole-body and truncal fat mass (all P < 0.050). Conclusions: The CR-modeled intervention had no effect on LVEF or biomarkers of cardiotoxicity. Future lifestyle intervention trials in patients with breast cancer should consider targeting other risk factors associated with incident cardiovascular disease. (Multidisciplinary Team IntervenTion in CArdio-ONcology [TITAN Study] [TITAN]; NCT01621659).
Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: A randomized controlled trial

Wei-Pang Chung,Hsin-Lun Yang,Ya-Ting Hsu,Ching-Hsia Hung,Ping-Yen Liu,Yen-Wen Liu,Shih-Hung Chan,Kun-Ling Tsai

DOI: https://doi.org/10.1016/j.rehab.2021.101485

IF: 5.393

2022-03-01

Annals of Physical and Rehabilitation Medicine

Abstract:BACKGROUND: Previous studies have reported that chemotherapy results in substantial long-term risk of heart failure. Exercise ameliorates exercise responses and exercise tolerance in patients receiving chemotherapy. The cardioprotective effect of real-time exercise in breast cancer is still unclear.OBJECTIVES: The aim of the present study was to determine the effect of real-time moderate-to-high-intensity exercise training in women with breast cancer undergoing chemotherapy and to follow up on parameters of cardiac function and exercise capacity at different times. We hypothesized that early moderate-to-high-intensity exercise training has beneficial effects on cardiac function in women with breast cancer undergoing chemotherapy.METHODS: This was a randomized controlled study that included 32 women randomly allocated into the control or exercise group. Exercise began with the first cycle of chemotherapy, and the training program was maintained during chemotherapy with 2 to 3 sessions per week for 3 months. Patients were instructed to perform moderate-to-high-intensity training with aerobic and resistance training. Outcome measurements were echocardiography and cardiopulmonary exercise test. The primary outcome was the change in left ventricle ejection fraction (LVEF). The secondary outcome was peak oxygen consumption (peak VO2).RESULTS: The control group showed lower cardiac systolic function than the exercise group [mean (SD) LVEF 62% (2) and 70% (5), P<0.05], reduced cardiac diastolic function, and cardiac hypertrophy at 3, 6 and 12 months after chemotherapy. At 6 months after chemotherapy, the exercise group exhibited relatively higher exercise capacity than controls [mean (SD) VO2 12.1 (2.2) and 13.6 (2.2) mL/kg/min, P<0.05]. The main effect size of the study based on echocardiography outcomes was 0.25 (95% confidence interval 0.23 to 0.27), a medium effect size.CONCLUSIONS: Moderate-to-high-intensity exercise training in breast cancer patients undergoing chemotherapy may prevent impaired cardiac function.CLINICAL TRIAL REGISTRATION: https://www.CLINICALTRIALS: in.th (Identifier TCTR20190330002).

rehabilitation
Fetomaternal alloimmune thrombocytopenia: The questions that still remain

J. Althaus,K. Blakemore

DOI: https://doi.org/10.1080/14767050701490517

2007-01-01

Abstract:Fetomaternal alloimmune thrombocytopenia (FMAIT) occurs when maternal antibodies are formed to fetal platelet antigens, leading to thrombocytopenia and hemorrhagic complications. The diagnosis is frequently made only after a major hemorrhagic event has occurred during a pregnancy. Identifying patients at risk remains difficult, and the optimal treatment regimen remains to be determined.
Effects of Aerobic Exercise on Cardiorespiratory Fitness, Cardiovascular Risk Factors, and Patient-Reported Outcomes in Long-Term Breast Cancer Survivors: Protocol for a Randomized Controlled Trial

Tormod Skogstad Nilsen,Mali Sæter,Sebastian Imre Sarvari,Kristin Valborg Reinertsen,Sara Hassing Johansen,Elisabeth Rustad Edvardsen,Jostein Hallén,Elisabeth Edvardsen,May Grydeland,Cecilie Essholt Kiserud,Hanne Cathrine Lie,Paul André Solberg,Torbjørn Wisløff,Adam Philip Sharples,Truls Raastad,Kristina Hermann Haugaa,Lene Thorsen

DOI: https://doi.org/10.2196/45244

2023-03-15

Abstract:Background: Anthracycline-based chemotherapy has been mainstay of adjuvant breast cancer therapy for decades. Although effective, anthracyclines place long-term breast cancer survivors at risk of late effects, such as reduced cardiorespiratory fitness and increased risk of cardiovascular disease. Previous research has shown beneficial effects of exercise training on cardiorespiratory fitness, but the effects of exercise on limiting factors for cardiorespiratory fitness, cardiovascular risk factors, and patient-reported outcomes in long-term survivors are less clear. Whether previous exposure to breast cancer therapy modulates the effects of exercise is also unknown. Objective: The primary aim of the CAUSE (Cardiovascular Survivors Exercise) trial is to examine the effect of aerobic exercise on cardiorespiratory fitness in anthracycline-treated long-term breast cancer survivors. Secondary aims are to examine effects of exercise training on limiting factors for cardiorespiratory fitness, cardiovascular risk factors, and patient-reported outcomes, and to compare baseline values and effects of exercise training between similar-aged women with and those without prior breast cancer. A third aim is to examine the 24-month postintervention effects of aerobic exercise on primary and secondary outcomes. Methods: The CAUSE trial is a 2-armed randomized controlled trial, where 140 long-term breast cancer survivors, 8-12 years post diagnosis, are assigned to a 5-month nonlinear aerobic exercise program with 3 weekly sessions or to standard care. Seventy similar-aged women with no history of cancer will undergo the same exercise program. Cardiorespiratory fitness measured as peak oxygen consumption (VO2peak), limiting factors for VO2peak (eg, cardiac function, pulmonary function, hemoglobin mass, blood volume, and skeletal muscle characteristics), cardiovascular risk factors (eg, hypertension, diabetes, dyslipidemia, obesity, physical activity level, and smoking status), and patient-reported outcomes (eg, body image, fatigue, mental health, and health-related quality of life) will be assessed at baseline, post intervention, and 24 months post intervention. Results: A total of 209 patients were included from October 2020 to August 2022, and postintervention assessments were completed in January 2023. The 24-month follow-up will be completed in February 2025. Conclusions: The findings from the CAUSE trial will provide novel scientific understanding of the potential benefits of exercise training in long-term breast cancer survivors. Trial registration: ClinicalTrials.gov NCT04307407; https://clinicaltrials.gov/ct2/show/NCT04307407. International registered report identifier (irrid): DERR1-10.2196/45244.
Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol

Stephen J Foulkes,Erin J Howden,Yoland Antill,Sherene Loi,Agus Salim,Mark J Haykowsky,Robin M Daly,Steve F Fraser,Andre La Gerche

DOI: https://doi.org/10.1186/s12885-020-07123-6

IF: 4.638

2020-07-14

BMC Cancer

Abstract:Background: Anthracycline chemotherapy (AC) is an efficacious (neo) adjuvant treatment for early-stage breast cancer (BCa), but is associated with an increased risk of cardiac dysfunction and functional disability. Observations suggest that regular exercise may be a useful therapy for the prevention of cardiovascular morbidity but it is yet to be interrogated in a large randomised trial. The primary aims of this study are to: 1) determine if 12-months of ET commenced at the onset of AC can reduce the proportion of BCa patients with functional disability (peak VO2, < 18 ml/kg/min), and 2) compare current standard-of-care for detecting cardiac dysfunction (resting left-ventricular ejection fraction assessed from 3-dimensional echocardiography) to measures of cardiac reserve (peak exercise cardiac output assessed from exercise cardiac magnetic resonance imaging) for predicting the development of functional disability 12-months following AC. Secondary aims are to assess the effects of ET on VO2peak, left ventricular morphology, vascular stiffness, cardiac biomarkers, body composition, bone mineral density, muscle strength, physical function, habitual physical activity, cognitive function, and multidimensional quality of life. Methods: One hundred women with early-stage BCa (40-75 years) scheduled for AC will be randomized to 12-months of structured exercise training (n = 50) or a usual care control group (n = 50). Participants will be assessed at baseline, 4-weeks following completion of AC (4-months) and at 12-months for all measures. Discussion: Women diagnosed with early-stage BCa have increased cardiac mortality. More sensitive strategies for diagnosing and preventing AC-induced cardiovascular impairment are critical for reducing cardiovascular morbidity and improving long-term health outcomes in BCa survivors. Trial registration: Australia & New Zealand Clinical Trials Registry (ANZCTR), ID: 12617001408370 . Registered on 5th of October 2017.
Low levels of tissue factor rescue protein C‐associated pregnancy failure in mice

A. Lay,C. Northway,D. Donahue,F. Castellino

DOI: https://doi.org/10.1111/j.1538-7836.2008.03085.x

2008-10-01

Journal of Thrombosis and Haemostasis

Abstract:We have previously demonstrated that maternal Protein C (PC) is critical for ensuring a successful pregnancy outcome [1]. Our findings suggested that enhanced coagulation, accompanied by elevated inflammation, due to a severe PC deficiency, were contributing causes of the failed pregnancies. Whether severe thrombosis at the fetal-maternal interface was the direct consequence of pregnancy failure was unclear. Furthermore, it was not apparent whether the enhanced recruitment of inflammatory cells was due to a PC deficiency and/or whether it was secondary to a local accumulation of fibrin or an excess of thrombin. To investigate whether severe coagulation was a significant factor in the pregnancy failure, we generated, by crossmating strategies, mice expressing very low levels of PC, combined with mice with a severe depletion in Tissue Factor (TF), i.e., PC−/−PC(tg4)/TF−/−hTF(tg). These lines of mice express PC and TF from nontargeted single allelic transgenic (tg) insertions of murine PC and human TF cDNAs, respectively, with the endogenous genes encoding these proteins totally inactivated through breeding strategies. Singly-deficient PC−/−PC(tg4) [1] and TF−/−hTF(tg) [2] mice each express PC and TF at approximately 1% of WT adult values. A significant (N = 6, P < 0.05) increase in the clottable fibrinogen level was observed in PC−/−(tg4) mice compared to WT mice (Figure 1a). However, mice with a combined severe deficiency of PC [PC−/−PC(tg4)], along with a ~99% reduction in TF [TF−/−hTF(tg)], restored fibrinogen to WT levels (N = 6, P < 0.05). Similarly, thrombin-antithrombin (TAT) levels (Figure 1b) responded to these genotypic manipulations in the same fashion as the fibrinogen levels (same samples as in Figure 1a; P < 0.05 for each genotype, compared to WT). These data suggest that the coagulopathy observed in PC−/−PC(tg4) mice was reversed by the additional severe deficiency of TF. Figure 1 Coagulopathy and hyperinflammatory responses in the ectoplacental cone regions of low-PC pregnant females are corrected by a simultaneous deficiency of TF Whereas PC−/−PC(tg4) females were not able to sustain pregnancies beyond midgestation (ED7.5–8.5), independent of the embryonic genotypes, PC−/−PC(tg4) mice, crossbred with mice with a severe reduction in TF levels (50% or 99% of WT), led to successful pregnancies. In particular, 15/15 pregnancies from PC−/−PC(tg4)/TF−/−hTF(tg) females x PC−/−PC(tg4)/TF+/−hTF(tg) males and 12/12 pregnancies from PC−/−PC(tg4)/TF−/−hTF(tg) females x PC−/−PC(tg4)/TF−/−hTF(tg) males, were successfully maintained to term. In these cases, live pups were born and survived at least to weaning age. Interestingly, these pregnancies produced an average of 3 pups/litter, suggesting that some embryos still failed to fully develop despite a reduction in the coagulopathy due to a severe PC deficiency. In addition, when 44 embryos from 10 matings of PC+/−PC(tg4)/TF+/−hTF(tg) females x PC−/−PC(tg4)/TF−/−hTF(tg) males were analyzed, 12 live offspring of the genotype PC+/−PC(tg4)/TF−/−hTF(tg) and 9 live offspring of the genotype PC−/−PC(tg4)/TF+/−hTF(tg) were found, numbers close to the theroetical value of 11 for each of these two genotypes. This indicates that elevation of the anticoagulant PC activity in a low-TF embryo, or an increase in procoagulant TF in a low-PC embryo, did not affect embryonic viabilities. To monitor the PC−/−PC(tg4)/TF−/−hTF(tg) x PC−/−PC(tg4)/TF−/−hTF(tg) pregnancies more closely, we followed the gestational progress from 7.5–13.5 dpc by exploratory surgeries to visualize yolk sacs from the uteri of pregnant mice. As predicted, a significant number of non-viable reabsorbing PC−/−PC(tg4)/TF−/−hTF(tg) fetuses (~6/litter) were detected at this time. The pregnancies spontaneously terminated at 7.5–8.5 dpc, confirmed histologically, which was a similar time of death of non-viable embryos from low-PC mothers [1]. Since these embryos were all of the same genotype, it appears as though the embryonic block in PC−/−PC(tg4) mothers was only partly restored by the additional decrease in TF levels, a nonetheless very significant result. In addition, it appeared that in the absence of overt thrombosis at the ectoplacental cone (EC) region (Figure 1c,d) in the PC−/−PC(tg4)/TF+/−hTF(tg) cohort, inflammation was also reduced, as seen by the significantly smaller numbers of leukocytes in this same area in this mouse line (Figure 1e,f). These findings suggested that the recruitment of inflammatory cells in low-PC mothers was a response to fibrin deposition, or to proteases generated from the TF-dependent coagulation cascade. The data also imply that hypercoagulation alone was not entirely responsible for embryonic death in low PC mothers, since some death persisted in very low TF/PC embryos, despite the absence of severe thrombosis. The evidence that only a fraction of embryos survived beyond the implantation stage in mothers with a compound severe deficiency of PC/TF further implies that improving normal hemostasis was not in itself sufficient to fully rescue embryonic death. We suggest that in addition to balancing hemostasis, activated PC (aPC)-dependent inflammatory signaling is required for sustaining embryonic viability. Findings from studies in mice deficient for thrombomodulin [3] and Endothelial Protein C Receptor (EPCR) [4] also support a role for aPC signaling in favorable pregnancy outcomes. In conclusion, this study shows that in the presence of a limited level of the anticoagulant, PC, placental homeostasis can be restored by reducing TF expression, thus facilitating proper embryonic implantation, similar to the TF-mediated rescue observed in EPCR−/− embryo [5]. The evidence of limited viable embryos in the low-PC mother supports our previous work showing that embryonic survival is highly dependent on the availability of maternal PC. This correlates to, and extends, the finding that EPCR expression only on placental giant trophoblasts allows embryos to be maintained to term [5]. We show here that this cannot be accomplished without maternal aPC. Thus, interfering with maternal aPC/giant trophoblast EPCR-mediated signaling is detrimental to the development of the embryo.
Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk: A Randomized Clinical Trial

Sofia Gonçalves Viamonte,Ana Vieira Joaquim,Alberto Jorge Alves,Eduardo Vilela,Andreia Capela,Cristina Ferreira,Barbara Fresco Duarte,Nuno Dias Rato,Madalena Pinheiro Teixeira,Aida Tavares,Mário Santos,Fernando Ribeiro

DOI: https://doi.org/10.1001/jamacardio.2023.3558

2023-12-01

Abstract:Importance: Cardiovascular disease is a leading cause of morbidity in cancer survivors, which makes strategies aimed at mitigating cardiovascular risk a subject of major contemporary importance. Objective: To assess whether a center-based cardiac rehabilitation (CBCR) framework compared with usual care encompassing community-based exercise training (CBET) is superior for cardiorespiratory fitness improvement and cardiovascular risk factor control among cancer survivors with high cardiovascular risk. Design, setting, and participants: This prospective, single-center, randomized clinical trial (CORE trial) included adult cancer survivors who had exposure to cardiotoxic cancer treatment and/or previous cardiovascular disease. Enrollment took place from March 1, 2021, to March 31, 2022. End points were assessed at baseline and after the 8-week intervention. Interventions: Participants were randomly assigned in a 1:1 ratio to 8 weeks of CBCR or CBET. The combined aerobic and resistance exercise sessions were performed twice a week. Main outcomes and measures: The powered primary efficacy measure was change in peak oxygen consumption (V̇o2) at 2 months. Secondary outcomes included handgrip maximal strength, functional performance, blood pressure (BP), body composition, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), lipid profile, plasma biomarker levels, physical activity (PA) levels, psychological distress, quality of life (QOL), and health literacy. Results: A total of 75 participants completed the study (mean [SD] age, 53.6 [12.3] years; 58 [77.3%] female), with 38 in the CBCR group and 37 in the CBET group. Participants in CBCR achieved a greater mean (SD) increase in peak V̇o2 than those in CBET (2.1 [2.8] mL/kg/min vs 0.8 [2.5] mL/kg/min), with a between-group mean difference of 1.3 mL/kg/min (95% CI, 0.1-2.6 mL/kg/min; P = .03). Compared with the CBET group, the CBCR group also attained a greater mean (SD) reduction in systolic BP (-12.3 [11.8] mm Hg vs -1.9 [12.9] mm Hg; P < .001), diastolic BP (-5.0 [5.7] mm Hg vs -0.5 [7.0] mm Hg; P = .003), and BMI (-1.2 [0.9] vs 0.2 [0.7]; P < .001) and greater mean (SD) improvements in PA levels (1035.2 [735.7] metabolic equivalents [METs]/min/wk vs 34.1 [424.4] METs/min/wk; P < .001), QOL (14.0 [10.0] points vs 0.4 [12.9] points; P < .001), and health literacy scores (2.7 [1.6] points vs 0.1 [1.4] points; P < .001). Exercise adherence was significantly higher in the CBCR group than in the CBET group (mean [SD] sessions completed, 90.3% [11.8%] vs 68.4% [22.1%]; P < .001). Conclusion and relevance: The CORE trial showed that a cardio-oncology rehabilitation model among cancer survivors with high cardiovascular risk was associated with greater improvements in peak V̇o2 compared with usual care encompassing an exercise intervention in a community setting. The CBCR also showed superior results in exercise adherence, cardiovascular risk factor control, QOL, and health literacy. Trial registration: ClinicalTrials.gov Identifier: NCT05132998.
Effectiveness of Aerobic Training for Adverse Symptoms Related to Chemotherapy During Treatment: Protocol for a Randomized Controlled Trial With Cost-Effectiveness Assessment

William de Lima Selles,Gisela Cristiane Miyamoto,Elinaldo da Conceição Santos,Cibelle Regina Lima Carmo,Giovanni Marini Moura,Giovanna Marques Frascoli Santos,Giovanna Dos Santos Lopes,Diego Wisnieski Silva,Leticia Jeremias Ferreira Pereira,Adriana Claudia Lunardi

DOI: https://doi.org/10.2196/60828

2024-08-20

Abstract:Background: One strategy to prevent adverse effects resulting from chemotherapy treatment is to perform physical exercises during treatment. However, there is still no consensus on the best type and intensity of exercise, nor when it should be started. Most studies have been carried out in patients with breast cancer, usually a few weeks after starting chemotherapy, on an outpatient basis 2 to 3 times a week. The main differences in our study are that we carried out physical training in hospitalized patients undergoing a cycle of chemotherapy for cancer treatment and that this training was carried out 5 times a week and was not restricted to a specific type of cancer. Objective: We aimed to evaluate the effects of aerobic training on symptoms related to chemotherapy (nausea, vomiting, asthenia, and sensation of weakness), fatigue, mobility, clinical complications, and length of hospital stay of patients during the drug treatment cycle. We also evaluated patient satisfaction with the proposed intervention, the adverse effects of aerobics training, and the cost-effectiveness of this intervention. Methods: This is a controlled and randomized trial with blinded evaluation that will include 94 hospitalized patients with cancer for 1 or more cycles of chemotherapy. The intervention group will perform aerobic training during a cycle of chemotherapy. The control group will receive a booklet with guidelines for staying active during the hospitalization period. The groups will be compared using a linear mixed model for fatigue, mobility, and chemotherapy-related symptoms before and after the intervention. The length of hospital stay will also be compared between groups using Kaplan-Meier survival analysis. The incidence of complications will be compared using the χ2 test. Cost-effectiveness and cost-utility analyses will be performed for the impact of exercise and quality-adjusted life years with the EQ-5D-3L-21 quality of life trials. The implementation variables (acceptability, suitability, and feasibility) will be evaluated by frequencies. Results: The clinical trial registration was approved in March 2023. Recruitment and data collection for the trial are ongoing, and the results of this study are likely to be published in late 2025. Conclusions: Chemotherapy has side effects that negatively impact the quality of life of patients with cancer. Aerobic exercise can reduce these side effects in a simple and inexpensive way. The field of work of physical therapists could be expanded to oncology if the intervention works. Trial registration: Registro Brasileiro de Ensaios Clínicos RBR-6b4zwx3; https://tinyurl.com/39c4c7wz. International registered report identifier (irrid): DERR1-10.2196/60828.
High intensity exercise during breast cancer chemotherapy - effects on long-term myocardial damage and physical capacity - data from the OptiTrain RCT

Josefin Ansund,Sara Mijwel,Kate A. Bolam,Renske Altena,Yvonne Wengström,Eric Rullman,Helene Rundqvist

DOI: https://doi.org/10.1186/s40959-021-00091-1

2021-02-15

Abstract:Abstract Background Adjuvant systemic breast cancer treatment improves disease specific outcomes, but also presents with cardiac toxicity. In this post-hoc exploratory analysis of the OptiTrain trial, the effects of exercise on cardiotoxicity were monitored by assessing fitness and biomarkers over the intervention and into survivorship. Methods; Women starting chemotherapy were randomized to 16-weeks of resistance and high-intensity interval training (RT-HIIT), moderate-intensity aerobic and high-intensity interval training (AT–HIIT), or usual care (UC). Outcome measures included plasma troponin-T (cTnT), Nt-pro-BNP and peak oxygen uptake (VO 2peak ), assessed at baseline, post-intervention, and at 1- and 2-years. Results For this per-protocol analysis, 88 women met criteria for inclusion. Plasma cTnT increased in all groups post-intervention. At the 1-year follow-up, Nt-pro-BNP was lower in the exercise groups compared to UC. At 2-years there was a drop in VO 2peak for patients with high cTnT and Nt-pro-BNP. Fewer patients in the RT-HIIT group fulfilled biomarker risk criteria compared to UC (OR 0.200; 95% CI = 0.055–0.734). Conclusions In this cohort, high-intensity exercise was associated with lower levels of NT-proBNP 1-year post-baseline, but not with cTnT directly after treatment completion. This may, together with the preserved VO 2peak in patients with low levels of biomarkers, indicate a long-term cardioprotective effect of exercise. Trial registration Clinicaltrials.govNCT02522260, Registered 13th of august 2015 – Retrospectively Registered Graphical abstract
Protective effects of exercise on cardiotoxicity induced by breast cancer treatments: A systematic review and meta-analysis

Alicia Fernández-Casas,Raquel Leirós-Rodríguez,Pablo Hernandez-Lucas,Alicia González-Represas

DOI: https://doi.org/10.1016/j.maturitas.2024.107932

IF: 5.11

2024-05-01

Maturitas

Abstract:OBJECTIVE: Currently, one of the main causes of death in women with breast cancer is cardiovascular disease caused by the oncologic therapies. Exercise has demonstrated positive effects on cardiovascular fitness in individuals without cancer. Therefore, the aim of this study was to evaluate the cardioprotective effects of exercise in women with breast cancer, during and after the application of their treatments.METHODS: Systematic search was done in PubMed, Scopus, Web of Science, CINAHL, MEDLINE, SPORTDiscus, and PEDro. The articles must have been published in the last ten years; the intervention to be evaluated was to consist of an exercise program; the sample had to comprise women who were undergoing breast cancer treatment or who had completed it at the time of the intervention; and the outcome variables had to include at least one parameter for the assessment of cardiac function and/or structure.RESULTS: Of the 28 articles identified, nine reported non-randomized controlled studies, 16 randomized clinical trials and three quasi-experimental studies. The effects of exercise on left ventricular ejection fraction, global longitudinal strain and the E/A waveforms ratio were not significant. However, its effect on VO2max was significant.CONCLUSIONS: Exercise does not seem to be effective in avoiding the cardiotoxic effects of oncological treatment for breast cancer. Although exercise seems to mitigate the symptomatology, reflected in improved functional capacity, more long-term studies are needed.PROSPERO REGISTRATION CODE: CRD42023391441.

obstetrics & gynecology,geriatrics & gerontology,gerontology
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

Andrea Moreno-Arciniegas,Alberto García,Malte Kelm,Francesco D'Amore,María Gomes da Silva,Javier Sánchez-González,Pedro L Sánchez,Teresa López-Fernández,Raul Córdoba,Riccardo Asteggiano,Vincent Camus,Jouke Smink,Antonio Ferreira,Marie J Kersten,Natacha Bolaños,Noemi Escalera,Elsa Pacella,Sandra Gómez-Talavera,Antonio Quesada,Xavier Rosselló,Borja Ibanez,RESILIENCE Trial Investigators,Alejandro Martín,Javier López,María Jesús Peñarrubia,Celina Benavente,Irene Sánchez Vadillo,Mariana Bastos,Ana Jiménez Ubieto,María Belén Navarro Eva González Barca,José Manuel Puerta,Guillermo Rodríguez,Antonio Berruezo,Jean-Nicolas Dacher,Arancha Alonso,Jose Angel Hernández Rivas,Julio García Suarez,Pierre Lebreton,Irene Sempere Rodríguez,Jesús Molina Carretero,Ignacio Polo Vaquero,Ángel Franch Manchón,Antonio Ureña Linde,Tamara Fernández Delgado,Samuel Pérez Fernández,Fernando Benito Valtueña,Manuel Desco Menéndez,María López Álvarez,Alba María Vega Viyuela,Laura Pardo Gambarte,Daniel Morillo Giles,María de Los Ángeles Pérez Saenz,Ester Macía Palafox,Sascha Dietrich,Ulrich Germing,Amin Polzin,Saskia Pietrucha,Fabian Voss,Chiara Berste,Peter Martin Hjørnet Kamper,Sanne Nagstrup Kjær,Won Yong Kim,Katrine Frikke Andersen,Maria do Céu Trindade,Diana Viegas,Vanessa Harres,Ece Ercan,Álvaro Navarro Guzmán,Fernando Gonçalves,Hervé Tilly,Fabrice Jardin,Aspasia Stamatoullas,Juliette Penichoux,Nathalie Contentin,Alexandra Zduniak,Mustafa Alani,Stephane Lepretre,Pascal Lenain,Florian Bouclet,Helene Lanic,Anne-Lise Menard,Emilie Lemasle,Sydney Dubois,Oana Brehar,Doriane Richard,Ridha Belilita,Aart J Nederveen,Esra Eyiis,Koen de Heer,Esther Agea,Alberto San Román,Carlos Baladrón,Ana Revilla-Orodea,Ana Martín-García,Candelas Perez Del Villar Moro,Norma Carmen Gutiérrez Gutiérrez,Ramón García-Sanz,Leticia Vicente Pacho,Clara Sanchez Pablo,Rosa María Tarradas,Begoña Navas Elorza,Gonzalo Del Campo Balguerías,Estefanía Bolaños Calderón,Javier Cucharero Martín,Raquel Gil,Paloma Pastor,Mireia Bañuls García,Alba Gutiérrez de la Peña,José Antonio García Vela,Gabriela De Aquino Palma,Sandra Gómez Lopera,Genaro López Milena,Mª José Rivero,María Del Pilar Serrano Gotarredona,Daniel Viveros,Alba Magliano,Mercedes Iglesias,Marina Huguet Pañella,Sébastien Normant,Alejandra Segado de la Torre,Mariana Tercero Mora,María Stefania Infante,Isabel González Gascón,Maria Angeles Foncillas García,Carolina Muñoz Novas,Raquel Fernandez Ordoño,Adrian Porcel Almendral,Ana Puchol Crespo,Elena Flores Ballester,Elena Magro Mazo,Isabel Gutierrez Jomarron,Juan Jose Gil Fdez,Marta Callejas Chavaria,Patricia Garcia Ramirez,Yolanda Martin Guerrero,Paola Villafuerte Gutierrez,Montserrat Lopez Rubio,Angélique Picard

DOI: https://doi.org/10.1002/ejhf.3395

2024-08-30

Abstract:Aims: There is a lack of therapies able to prevent anthracycline cardiotoxicity (AC). Remote ischaemic conditioning (RIC) has shown beneficial effects in preclinical models of AC. Methods: REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE) is a multinational, prospective, phase II, double-blind, sham-controlled, randomized clinical trial that evaluates the efficacy and safety of RIC in lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles including anthracyclines and with ≥1 AC-associated risk factors will be randomized to weekly RIC or sham throughout the chemotherapy period. Patients will undergo three multiparametric cardiac magnetic resonance (CMR) studies, at baseline, after the third cycle (intermediate CMR), and 2 months after the end of chemotherapy. Thereafter, patients will be followed up for clinical events over an anticipated median of ≥24 months. The primary endpoint is the absolute change from baseline in CMR-based left ventricular ejection fraction (LVEF). The main secondary outcome is the incidence of AC events, defined as (1) a drop in CMR-based LVEF of ≥10 absolute points, or (2) a drop in CMR-based LVEF of ≥5 and <10 absolute points to a value <50%. Intermediate CMR will test the ability of T2 mapping to predict AC versus classical markers (left ventricular strain and cardiac injury biomarkers). A novel CMR sequence allowing ultrafast cine acquisition will be validated in this vulnerable population. Conclusions: The RESILIENCE trial will test RIC (a novel non-invasive intervention to prevent AC) in a cohort of high-risk patients. The trial will also test candidate markers for their capacity to predict AC and will validate a novel CMR sequence reducing acquisition time in a vulnerable population.
Association of anthropometric variables with therapy-induced cardiotoxicity in women with breast cancer: a pilot study for a randomized clinical trial

Karini Merolillo,Maria Inês González Solari,Tayani Palma Cohen,Andreas Lutz,Patricia de Carvalho,Fabio Cañellas,Diogo Rech,Otávio de Carvalho,Alice Zelmanowicz,Alexandre Machado Lehnen,Nance Nardi,Natalia Motta Leguisamo

DOI: https://doi.org/10.1186/s40959-024-00258-6

2024-09-04

Abstract:Background: Doxorubicin (DOX) has been widely used in the treatment of breast cancer, but it is directly associated with late-onset cardiovascular disease (CVD). Whether anthropometric, food intake or other risk factors together with DOX-based chemotherapy can increase the risk of developing cardiotoxicity remains uncertain. We examined the association between anthropometric variables with doxorubicin-induced cardiotoxicity in women with breast cancer. Methods: Twenty-six women (53.7 ± 9.6 y) undergoing DOX-based chemotherapy (408.3 ± 66.7 mg/m2) participated in the study. We collected data on body composition (bioimpedance), dietary intake (24 h) and cardiac function (echocardiographic assessment of left ventricular ejection fraction, LVEF). All measurements were taken at baseline, one month of treatment completion and one-year follow-up after start of treatment. DOX-induced cardiotoxicity was defined as ≥ 10% absolute decrease in LVEF. Thus, the participants were then grouped as DOX-induced (DIC) or non-DOX-induced (non-DIC) cardiotoxicity. Data are shown as mean ± SD (standard deviation). We performed comparisons between the two groups using Student's t-test for independent samples or Generalized Estimating Equations (groups + 3 evaluation time points) with Bonferroni post-hoc test. Lastly, the correlations were analyzed using Pearson correlation; p < 0.05 for all tests. Results: At baseline the participants' body mass index (BMI) was 29.9 ± 7.9 kg/m2 and LVEF was 67.4 ± 6.2%. Seven of them (26.9%) developed therapy-induced cardiotoxicity (ΔLVEF - 3.2 ± 2.6%; p < 0.001). Postmenopausal status and family history of CVD were more prevalent in the DIC group than non-DIC group. We found no consistent BMI changes in the groups over time. Interestingly, the non-DIC group showed a small increase in visceral fat at treatment completion and increased waist circumference at one-year follow-up compared to baseline. These same changes were not seen in the DIC group. We also observed a pattern of correlation of some anthropometric variables with LVEF: the more unfavorable the body composition the more pronounced the LVEF decrease at one-year follow-up, though not associated with cardiotoxicity. Conclusions: Our study did not provide sufficient evidence to support that anthropometric variables, food intake or other risk factors increase the risk of developing cardiotoxicity. However, there are apparent trends that need to be further investigated in larger samples.
High-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE RCT

Peter Henriksen,Morag MacLean,Marek Atter,Steff Lewis,Aryelly Rodriguez

DOI: https://doi.org/10.3310/aptu2400

2024-08-01

Efficacy and Mechanism Evaluation

Abstract:Background Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by rises in plasma cardiac troponin concentrations. Beta-adrenergic receptor blocker and renin-angiotensin-system inhibitor therapies have been associated with modest cardioprotective effects in unselected patients receiving anthracycline chemotherapy. Methods In a multicentre prospective randomised open-label blinded end-point trial, patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy underwent plasma high-sensitivity cardiac troponin concentration monitoring and cardiac magnetic resonance imaging before and 6 months after anthracycline treatment. Randomised controlled trial – patients at high risk of cardiotoxicity (plasma cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomised to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone. The primary end point was 6-month change in left ventricular ejection fraction. Prognostic cohort study – in low-risk non-randomised patients with plasma cardiac troponin I concentrations in the lower two tertiles, we hypothesised the absence of a 6-month change in left ventricular ejection fraction (± 2%). Results Between October 2017 and June 2021, 175 patients (mean age 53 years; 87% female; 71% breast cancer) were recruited. Patients randomised to cardioprotection ( n = 29) or standard care ( n = 28) had mean left ventricular ejection fractions of 65.7 ± 6.6% and 64.9 ± 5.9%, respectively, at 6 months. Twenty patients (68.9%) were adherent to cardioprotection therapy at 6 months. Adverse events were more commonly reported in the cardioprotection group, with 71.4% of patients having at least one adverse event compared with 12.7% non-randomised and 10.3% standard care patients. After adjusting for age, pre-treatment left ventricular ejection fraction and planned anthracycline dose, the estimated mean percentage-point difference in 6-month left ventricular ejection fraction between the cardioprotection and standard care groups was –0.4% (95% confidence interval –3.59 to 2.85%; p = 0.82). In low-risk non-randomised patients, baseline and 6-month left ventricular ejection fractions were 69.3 ± 5.7% and 66.4 ± 6.3%, respectively (estimated mean difference 2.9%, 95% confidence interval 1.45 to 4.28%; p = 0.92, not equivalent). The main secondary objective of demonstrating zero percentage-point change with equivalence of ± 2% was not met. Conclusions Combination candesartan and carvedilol therapy had no demonstrable cardioprotective effect in patients receiving anthracycline-based chemotherapy with high-risk on-treatment plasma cardiac troponin I concentrations. Low-risk non-randomised patients had similar modest declines in left ventricular ejection fraction, suggesting that the clinical utility of routine cardiac troponin monitoring remains undefined. The modest short-term declines in left ventricular ejection fraction suggest that early cardioprotection therapy has a limited role in patients receiving anthracycline-based chemotherapy. Limitations Treatment effect might have been influenced by several patients stopping cardioprotection treatment within 2 months of randomisation. Across all groups, reduction in left ventricular ejection fraction was lower than expected and patients with high-risk cardiac troponin I concentrations did not exhibit a greater fall in left ventricular ejection fraction than low-risk patients. These factors, together with the trial being powered to detect a 5-percentage-point change in left ventricular ejection fraction, mean that a small treatment effect was not excluded. Future work Future work should aim to understand the transition from small changes in cardiac function, 6 months after completion of anthracycline chemotherapy, to the late development of heart failure in this population. Trial registration This trial is registered as ISRCTN24439460 and EudraCT 2017-000896-99. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 15/48/20) and is published in full in Efficacy and Mechanism Evaluation ; Vol. 11, No. 12. See the NIHR Funding and Awards website for further award information.
Effects of High and Low-To-Moderate Intensity Exercise During (Neo-) Adjuvant Chemotherapy on Muscle Cells, Cardiorespiratory Fitness, and Muscle Function in Women With Breast Cancer: Protocol for a Randomized Controlled Trial

Olav Vikmoen,Tor Helge Wiestad,Inger Thormodsen,Karin Nordin,Sveinung Berntsen,Ingrid Demmelmaier,Emelie Strandberg,Truls Raastad

DOI: https://doi.org/10.2196/40811

2022-11-12

JMIR Research Protocols

Abstract:Background: (Neo-)adjuvant chemotherapy for breast cancer is effective but has deleterious side effects on muscle tissue, resulting in reduced skeletal muscle mass, muscle function, and cardiorespiratory fitness. Various exercise regimens during cancer treatment have been shown to counteract some of these side effects. However, no study has compared the effect of high-intensity training versus low-to-moderate intensity training on muscle tissue cellular outcomes and physical function in patients with breast cancer during chemotherapy. Objective: The aim of this substudy within the Physical Training in Cancer (Phys-Can) consortium is to evaluate and compare the effects of high and low-to-moderate intensity exercise on muscle cellular outcomes, muscle function, and cardiorespiratory fitness in women with breast cancer undergoing (neo-)adjuvant chemotherapy. We further aim to investigate if the effects of chemotherapy including taxanes on muscles will be different from those of taxane-free chemotherapy. Methods: Eighty women recently diagnosed with breast cancer scheduled to start (neo-)adjuvant chemotherapy will be randomized to a combination of strength and endurance training, either at high intensity or at low-to-moderate intensity. Testing of muscle function and cardiorespiratory fitness and collection of muscle biopsies from the vastus lateralis muscle will be performed before the first cycle of chemotherapy (or after 1 week, when not possible) (T0), halfway through chemotherapy (T1), and after completion of chemotherapy (T2). It is estimated that approximately 50% of the participants will be willing to undergo muscle biopsies. To separate the effect of the treatment itself, a usual care group with no supervised training will also be included, and in this group, testing and collection of muscle biopsies will be performed at T0 and T2 only. Results: This study is funded by Active Against Cancer (Aktiv mot kreft) (May 2013) and the Norwegian Cancer Society (December 2018). Inclusion started in December 2016 and the last participant is expected to be recruited in December 2022. As of June 2022, we enrolled 38 (19 with biopsies) participants to the high-intensity training group, 36 (19 with biopsies) participants to the low-to-moderate intensity training group, and 17 (16 with biopsies) participants to the usual care group. Data analyses will start in fall 2022. The first results are expected to be published in spring 2024. Conclusions: This study will generate new knowledge about the effects of different training intensities for women with breast cancer during chemotherapy treatment. It will give further insight into how chemotherapy affects the muscle tissue and how physical training at different intensities may counteract the treatment side effects in muscles. The results of this study will inform the development and refinement of exercise programs that are effective and compatible with the multidisciplinary management of breast cancer. Trial Registration: ClinicalTrials.gov NCT05218876; https://tinyurl.com/ysaj9dhm
Attracting and retaining nurses in primary care.

V. Drennan,S. Andrews,R. Sidhu,R. Peacock

DOI: https://doi.org/10.12968/BJCN.2006.11.6.21218

2006-06-01

British Journal of Community Nursing

Abstract:There is increasing demand for nurses to work in primary care. This is driven in part by the need to retain current levels but also by the modernisation plans for primary care services, which require new roles for nurses, new ways of working and more nurses in primary care settings. While campaigns for increased recruitment of hospital nurses and doctors has been largely successful in recent years, primary care has still to see the impact. This article reports on a Department of Health (England) funded project that aimed to identify strategies and exemplars to assist primary care trusts (PCTs) and the workforce development confederations (WDCs) in strategic health authorities in attracting and retaining nurses to primary care at registered nurse level. It reports on the range of initiatives identified, the perceived benefits and challenges. It concludes by proposing a strategic model for planning for the recruitment and retention of primary care nurses.
Neo-train: study protocol and feasibility results for a two-arm randomized controlled trial investigating the effect of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer

Eva Kjeldsted,Gunn Ammitzbøll,Lars Bo Jørgensen,Alexey Lodin,Rasmus Dahlin Bojesen,Silvia Gonzalez Ceballos,Susanne Rosthøj,Anne-Vibeke Lænkholm,Søren T Skou,Sandy Jack,Julie Gehl,Susanne Oksbjerg Dalton

DOI: https://doi.org/10.1186/s12885-023-11284-5

IF: 4.638

2023-08-19

BMC Cancer

Abstract:Background: Prehabilitation with exercise interventions during neoadjuvant chemotherapy (NACT) is effective in reducing physical and psychosocial chemotherapy-related adverse events in patients with cancer. In preclinical studies, data also support a growth inhibitory effect of aerobic exercise on the tumour microenvironment with possible improved chemotherapy delivery but evidence in human patients is limited. The aim of the study here described is to investigate if supervised exercise with high-intensity aerobic and resistance training during NACT can improve tumour reduction in patients with breast cancer. Methods: This parallel two-armed randomized controlled trial is planned to include 120 women aged ≥ 18 years with newly diagnosed breast cancer starting standard NACT at a university hospital in Denmark (a total of 90 participants needed according to the power calculation and allowing 25% (n = 30) dropout). The participants will be randomized to usual care or supervised exercise consisting of high-intensity interval training on a stationary exercise bike and machine-based progressive resistance training offered three times a week for 24 weeks during NACT, and screening-based advice to seek counselling in case of moderate-severe psychological distress (Neo-Train program). The primary outcome is tumour size change (maximum diameter of the largest lesion in millimetre) measured by magnetic resonance imaging prior to surgery. Secondary outcomes include clinical/pathological, physical and patient-reported measures such as relative dose intensity of NACT, hospital admissions, body composition, physical fitness, muscle strength, health-related quality of life, general anxiety, depression, and biological measures such as intratumoural vascularity, tumour infiltrating lymphocytes, circulating tumour DNA and blood chemistry. Outcomes will be measured at baseline (one week before to 1-2 weeks after starting NACT), during NACT (approximately week 7, 13 and 19), pre-surgery (approximately week 21-29), at surgery (approximately week 21-30) and 3 months post-surgery (approximately 33-42 weeks from baseline). Discussion: This study will provide novel and important data on the potential benefits of supervised aerobic and resistance exercise concomitant to NACT on tumour response and the tumour microenvironment in patients with breast cancer, with potential importance for survival and risk of recurrence. If effective, our study may help increase focus of exercise as an active part of the neoadjuvant treatment strategy. Trial registration: The trial was registered at ClinicalTrials.gov (NCT04623554) on November 10, 2020.

[A new case of complete isolated diphallus].

Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast Cancer chemotherapy: The ONCORE randomized controlled trial

Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)

Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study

Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study

TITAN Trial: A Randomized Controlled Trial of a Cardiac Rehabilitation Care Model in Breast Cancer

Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: A randomized controlled trial

Fetomaternal alloimmune thrombocytopenia: The questions that still remain

Effects of Aerobic Exercise on Cardiorespiratory Fitness, Cardiovascular Risk Factors, and Patient-Reported Outcomes in Long-Term Breast Cancer Survivors: Protocol for a Randomized Controlled Trial

Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol

Low levels of tissue factor rescue protein C‐associated pregnancy failure in mice

Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk: A Randomized Clinical Trial

Effectiveness of Aerobic Training for Adverse Symptoms Related to Chemotherapy During Treatment: Protocol for a Randomized Controlled Trial With Cost-Effectiveness Assessment

High intensity exercise during breast cancer chemotherapy - effects on long-term myocardial damage and physical capacity - data from the OptiTrain RCT

Protective effects of exercise on cardiotoxicity induced by breast cancer treatments: A systematic review and meta-analysis

Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

Association of anthropometric variables with therapy-induced cardiotoxicity in women with breast cancer: a pilot study for a randomized clinical trial

High-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE RCT

Effects of High and Low-To-Moderate Intensity Exercise During (Neo-) Adjuvant Chemotherapy on Muscle Cells, Cardiorespiratory Fitness, and Muscle Function in Women With Breast Cancer: Protocol for a Randomized Controlled Trial

Attracting and retaining nurses in primary care.

Neo-train: study protocol and feasibility results for a two-arm randomized controlled trial investigating the effect of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer